IGC Pharma, Inc. Presenting 6 Posters on the Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference
View the full release here: https://www.businesswire.com/news/home/20230718231297/en/
- View the full release here: https://www.businesswire.com/news/home/20230718231297/en/
IGC Presenting Positive Impact of IGC-AD1 on Neuropsychiatric Symptoms in Dementia at the 2023 Alzheimer’s Association International Conference (Photo: Business Wire)
IGC-AD1 is the only natural low-doses THC-based investigational drug undergoing FDA trials. - The therapy relies on low doses of THC and another compound as active agents for the treatment of neuropsychiatric symptoms associated with Alzheimer’s disease.
- It has also shown in pre-clinical trials the potential to be effective in ameliorating Aβ plaque, a key hallmark of Alzheimer’s.
- IGC-AD1 is currently in Phase 2 of clinical trials as a potential treatment for agitation in dementia due to Alzheimer’s.